Vanguard Capital Management
TCRX icon

Vanguard Capital Management’s TScan Therapeutics TCRX Stock Holding History

Vanguard Capital Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.12M Buy
2,158,831
+4,575
+0.2% +$4.88K ﹤0.01% 3406
2026
Q1 		$2.18M Buy
+2,154,256
New +$2.3M ﹤0.01% 3335

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's TCRX Position: Q2 2026 in Review

Vanguard Capital Management increased its TScan Therapeutics (TCRX) stake by 0.21% in Q2 2026, buying an estimated $4.88K and bringing the position to 2,158,831 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3406.

Vanguard Capital Management first reported a position in TCRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.18M in Q1 2026. 51 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Vanguard Capital Management held 2,158,831 shares of TScan Therapeutics worth $2.12M as of Q2 2026.
  • Vanguard Capital Management bought 4,575 TScan Therapeutics shares in Q2 2026, an estimated $4.88K.
  • TScan Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3406 holding.
  • Vanguard Capital Management first reported a position in TScan Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's TScan Therapeutics position peaked at $2.18M in Q1 2026.
  • 51 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.